Company Plans to Report Phase 1 Interim Analysis for RE104 in Q1 2023 and Include Data Differentiating its Safety, Tolerability and Pharmacodynamic Profile from Other Psychedelics in Clinical Development On Track to Dose First Patient in Phase 2 Postpartum Depression Study in 2H 2023 President and CEO Presenting at Biotech Showcase in San Francisco on Jan. 9 TORONTO, Jan. 04, 2023 (GLOBE NEWSWIRE)…
Source